← Back to headlines
Summit Therapeutics Plans Interim PFS Analysis for HARMONi-3 Squamous Cohort
Summit Therapeutics announced plans to conduct an interim progression-free survival (PFS) analysis for its HARMONi-3 squamous cohort in the second quarter of 2026, as the company continues to expand its clinical pipeline.
24 Feb, 08:55 — 24 Feb, 08:55
Sources
Showing 1 of 1 sources
Related Stories
UNICEF Report Finds 20 Million Children Annually Face Online Sexual Exploitation
41m ago
Genetically Modified Pig Kidney Keeps US Patient Alive for Record Nine Months
57m ago
Pentagon Temporarily Rescinds Testosterone Screening Guidance for Troops
3h ago
RFK Jr. Allegedly Requested Removal of Measles Deaths From CDC Tally
4h ago